What is your approach to CMV prophylaxis in the post-allogeneic stem cell transplant setting?

We do not routinely use letermovir but we are looking carefully at this data.

We use prophylactic ganciclovir pre transplant and high dose acyclovir post transplant in high risk patients and are reviewing this data as well.